Łukasiewicz Sergiusz, Czeczelewski Marcin, Forma Alicja, Baj Jacek, Sitarz Robert, Stanisławek Andrzej
Department of Surgical Oncology, Center of Oncology of the Lublin Region St. Jana z Dukli, 20-091 Lublin, Poland.
Department of Forensic Medicine, Medical University of Lublin, 20-090 Lublin, Poland.
Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287.
Breast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. Its incidence and death rates have increased over the last three decades due to the change in risk factor profiles, better cancer registration, and cancer detection. The number of risk factors of BC is significant and includes both the modifiable factors and non-modifiable factors. Currently, about 80% of patients with BC are individuals aged >50. Survival depends on both stage and molecular subtype. Invasive BCs comprise wide spectrum tumors that show a variation concerning their clinical presentation, behavior, and morphology. Based on mRNA gene expression levels, BC can be divided into molecular subtypes (Luminal A, Luminal B, HER2-enriched, and basal-like). The molecular subtypes provide insights into new treatment strategies and patient stratifications that impact the management of BC patients. The eighth edition of TNM classification outlines a new staging system for BC that, in addition to anatomical features, acknowledges biological factors. Treatment of breast cancer is complex and involves a combination of different modalities including surgery, radiotherapy, chemotherapy, hormonal therapy, or biological therapies delivered in diverse sequences.
乳腺癌(BC)是全球女性中最常被诊断出的癌症,2020年新增病例超过200万例。在过去三十年中,由于风险因素分布的变化、更好的癌症登记和癌症检测,其发病率和死亡率有所上升。乳腺癌的风险因素众多,包括可改变因素和不可改变因素。目前,约80%的乳腺癌患者为年龄大于50岁的个体。生存率取决于分期和分子亚型。浸润性乳腺癌包括范围广泛的肿瘤,这些肿瘤在临床表现、行为和形态方面存在差异。基于mRNA基因表达水平,乳腺癌可分为分子亚型(Luminal A、Luminal B、HER2富集型和基底样型)。分子亚型为新的治疗策略和患者分层提供了见解,这些对乳腺癌患者的管理产生影响。第八版TNM分类法概述了一种新的乳腺癌分期系统,该系统除了解剖学特征外,还考虑了生物学因素。乳腺癌的治疗很复杂,涉及多种不同治疗方式的联合,包括手术、放疗、化疗、激素治疗或按不同顺序进行的生物治疗。